|
Patients diagnosed with Acute Hereditary Angioedema
Summary
The purpose of this study is to evaluate immunogenicity (ability to trigger an immune response) and hypersensitivity (undesirable reaction produced by the immune system) upon exposure to an FDA approved medication for patients who suffer from sudden HAE attacks.
Description
Winthrop University Hospital Clinical Trials Center is Seeking participants that are at least 16 years of age and have been diagnosed with Acute Hereditary Angioedema. Hereditary Angioedema (HAE) is a very rare and potentially life-threatening genetic condition that occurs in about 1 in 10,000 to 1 in 50,000 people. HAE symptoms include episodes of swelling in various body parts including the hands, feet, face and airway. Patients may also have bouts of excruciating abdominal pain, nausea and vomiting that is caused by swelling in the intestinal wall. Airway swelling is particularly dangerous and can lead to death by asphyxiation
Inclusion/exclusion
To be eligible for this clinical research study, you must; ??Be 16 years old or older ??Have been diagnosed with Acute Hereditary Angioedema
Principal Investigator
Mark Davis-Lorton, MD
Department
Allergy & Immunology
Email
clintrials@winthrop.org
Other Contact
For more information please call: 516-663-9582
|
